Clinical efficacy and safety of lornoxicam vs tramadol patient controlled analgesia in hepatocellular carcinoma patients treated with surgery
10.13699/j.cnki.1001-6821.2015.10.010
- VernacularTitle:氯诺昔康与曲马多对肝癌术后自控镇痛的临床疗效及安全性评价
- Author:
Sheng-Lin PEI
1
;
Lin RUAN
;
Ling-Hui PAN
;
Bing HUANG
;
Yu HUANG
;
Wan-Yun GE
Author Information
1. 广西医科大学 附属肿瘤医院 麻醉科
- Keywords:
lornoxicam;
tramadol;
hepatocellular carcinoma;
patient controlled analgesia;
adverse event
- From:
The Chinese Journal of Clinical Pharmacology
2015;(10):799-801
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the analgesia effect of lornoxicam versus tramadol patient controlled analgesia in hepatocellular carcinoma patients treated with surgery .Methods A total of 54 hepatocellular car-cinoma patients who were scheduled for operation were included , 28 pa-tients received lornoxicam patients controlled analgesia with lornoxicam 96 mg+0.9% NaCl up to 150 mL.And 26 patients received tramadol patients controlled analgesia with tramadol 96 mg+0.9%NaCl up to 150 mL.The visual analogue scale ( VAS ) and bruggrmann comfort scale (BCS) were recorded in the time point of 4,12,24 and 48 h.The adverse event such as nausea , vomiting and dizziness were compared between the two groups.Results The VAS and BCS had no statistical difference between the two group in each of the time points ( P>0.05 ) . The adverse event incidence were 14.3% and 19.2% in the lornoxicam and tramadol group respectively with no statistical difference ( P>0.05 ) . Conclusion Both lornoxicam versus tramadol were effective in patient con-trolled analgesia for hepatocellular carcinoma patients treated with surgery .
